Maen Abdelrahim, MD, PhD, B Pharm

Associate Professor of Medicine in Oncology, Academic Institute
Director, Cockrell Center for Advanced Therapeutics; Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Abdelrahim completed pharmacy training followed by graduate work in the field of pharmacology and toxicology. Upon completion of his graduate work, clinical training as a medical oncologist fueled his motivation and expertise in the field of anticancer drug discovery.

His translational research focus is on the discovery and development of new anticancer drugs. He has identified for the first time a new structural class of compounds that can target selective transcription factor called Sp proteins. Transcription factors are now recognized as targets for the development of new anticancer drugs. 

Description of Research

  • Targeted therapy in GI cancer
  • Immunotherapy
  • T cell therapy 

Dr. Abdelrahim's research has pinpointed few compounds that inhibit tumor growth and angiogenesis in-part by inducing proteasome-dependent degradation of selected Sp proteins in cancer cells and tumors. The lead compound of this class (Tolfenamic acid) has reached Phase I Clinical Trial to treat patients with advanced and metastatic pancreatic cancer in combination with gemcitabine and radiation therapy. Dr. Abdelrahim has a patent application submitted for the new use of these compounds in GI cancers. In prior research, he was the first to find that Sp4 protein is over expressed in GI cancers including pancreatic cancer and that the role of Sp4 can be equally important as Sp1 in some type of GI cancers.

Researchers in cancer have the ultimate responsibility of taking their findings to the clinic which is described as translational research. By seeing GI cancer patients in his practice, collaborating with translational scientist in the lab and conducting and directing clinical trials, Dr. Abdelrahim hopes to continue to fuel the translational research cycle from lab to clinic and back to the lab.

 

Areas Of Expertise

Clinical trials Gastrointestinal cancer Clinical research Translation research
Education & Training

Internship, Baylor College of Medicine
Fellow, Duke University Medical Center
MD, Texas A&M Health Science Center College of Medicine
PhD, Texas A&M University
B Pharm, Isra University
Publications

Transcription factors specificity protein and nuclear receptor 4A1 in pancreatic cancer
Safe, S, Mohankumar, K, Howard, M, Shrestha, R, Hedrick, E & Abdelrahim, M 2021, , World Journal of Gastroenterology, vol. 27, no. 38, pp. 6387-6398. https://doi.org/10.3748/wjg.v27.i38.6387

Transplant oncology: An evolving field in cancer care
Abdelrahim, M, Esmail, A, Abudayyeh, A, Murakami, N, Saharia, A, McMillan, R, Victor, D, Kodali, S, Shetty, A, Fong, JVN, Moore, LW, Heyne, K, Gaber, AO & Ghobrial, RM 2021, , Cancers, vol. 13, no. 19, 4911. https://doi.org/10.3390/cancers13194911

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
Yu, KH, Hendifar, AE, Alese, OB, Draper, A, Abdelrahim, M, Burns, E, Khan, G, Cockrum, P, Bhak, RH, Nguyen, C, DerSarkissian, M, Duh, MS & Bahary, N 2021, , Frontiers in Oncology, vol. 11, pp. 678070. https://doi.org/10.3389/fonc.2021.678070

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
Yu, KH, Hendifar, AE, Alese, OB, Draper, A, Abdelrahim, M, Burns, E, Khan, G, Cockrum, P, Bhak, RH, Nguyen, C, DerSarkissian, M, Duh, MS & Bahary, N 2021, , Frontiers in Oncology, vol. 11, 678070. https://doi.org/10.3389/fonc.2021.678070

Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
Abdelrahim, M, Mamlouk, O, Lin, H, Lin, J, Page, V, Abdel-Wahab, N, Swan, JT, Selamet, U, Yee, C, Diab, A, Suki, W & Abudayyeh, A 2021, , OncoImmunology, vol. 10, no. 1, 1927313. https://doi.org/10.1080/2162402X.2021.1927313

Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
Abdelrahim, M, Mamlouk, O, Lin, H, Lin, J, Page, V, Abdel-Wahab, N, Swan, J, Selamet, U, Yee, C, Diab, A, Suki, W & Abudayyeh, A 2021, , OncoImmunology, vol. 10, no. 1, 1927313, pp. 1927313. https://doi.org/10.1080/2162402X.2021.1927313

Hepatitis B Virus Reactivation in Cancer Patients Treated with Immune Checkpoint Inhibitors
Burns, EA, Muhsen, IN, Anand, K, Xu, J, Umoru, G, Arain, AN & Abdelrahim, M 2021, , Journal of Immunotherapy, vol. 44, no. 3, pp. 132-139. https://doi.org/10.1097/CJI.0000000000000358

The latest advancement in pancreatic ductal adenocarcinoma therapy: A review article for the latest guidelines and novel therapies
Elsayed, M & Abdelrahim, M 2021, , Biomedicines, vol. 9, no. 4, 389. https://doi.org/10.3390/biomedicines9040389

New Breakthroughs for Liver Transplantation of Cholangiocarcinoma
McMillan, RR, Saharia, A, Abdelrahim, M & Ghobrial, RM 2021, , Current Transplantation Reports, vol. 8, no. 1, pp. 21-27. https://doi.org/10.1007/s40472-021-00313-6

Infliximab for the treatment of patients with checkpoint inhibitor–associated acute tubular interstitial nephritis
Lin, JS, Mamlouk, O, Selamet, U, Tchakarov, A, Glass, WF, Sheth, RA, Layman, RM, Dadu, R, Abdelwahab, N, Abdelrahim, M, Diab, A, Yee, C & Abudayyeh, A 2021, , OncoImmunology, vol. 10, no. 1, 1877415. https://doi.org/10.1080/2162402X.2021.1877415

A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant
Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium 2021, , Kidney international, vol. 100, no. 1, pp. 196-205. https://doi.org/10.1016/j.kint.2020.12.015

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
Lin, JS, Wang, DY, Mamlouk, O, Glass, WF, Abdelrahim, M, Yee, C & Abudayyeh, A 2020, , Journal for immunotherapy of cancer, vol. 8, no. 2, e001287. https://doi.org/10.1136/jitc-2020-001287

Commentary on Neoadjuvant Versus Surgery First Approach in Resectable Pancreatic Ductal Adenocarcinoma
Saharia, A, Potter, L, Baio, F, Elshawwaf, M, Abdelrahim, M & Heyne, K 2020, , American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 43, no. 10, pp. 753-754. https://doi.org/10.1097/COC.0000000000000743

Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients
Abudayyeh, A, Lin, H, Abdelrahim, M, Rondon, G, Andersson, BS, Martinez, CS, Page, VD, Tarrand, JJ, Kontoyiannis, DP, Marin, D, Oran, B, Olson, A, Jones, R, Popat, U, Champlin, RE, Chemaly, RF, Shpall, EJ & Rezvani, K 2020, , Transplant Infectious Disease, vol. 22, no. 5, e13395. https://doi.org/10.1111/tid.13395

Renal Replacement Therapy in Patients With Stage IV Cancer Admitted to the Intensive Care Unit With Acute Kidney Injury at a Comprehensive Cancer Center Was Not Associated With Survival
Abudayyeh, A, Song, J, Abdelrahim, M, Dahbour, I, Page, VD, Zhou, S, Shen, C, Zhao, B, Pai, RN, Amaram-Davila, J, Manzano, JG, George, MC, Yennu, S, Mandayam, SA, Nates, JL & Moss, AH 2020, , American Journal of Hospice and Palliative Medicine, vol. 37, no. 9, pp. 707-715. https://doi.org/10.1177/1049909120902115

Checkpoint inhibitor-related renal vasculitis and use of rituximab
Mamlouk, O, Lin, JS, Abdelrahim, M, Tchakarov, AS, Glass, WF, Selamet, U, Buni, M, Abdel-Wahab, N & Abudayyeh, A 2020, , Journal for immunotherapy of cancer, vol. 8, no. 2. https://doi.org/10.1136/jitc-2020-000750

Acquired haemophilia as a paraneoplastic manifestation of pancreatic cancer
Arain, A, Muhsen, IN & Abdelrahim, M 2020, , ecancermedicalscience, vol. 14, 1053. https://doi.org/10.3332/ECANCER.2020.1053

Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer (Cancer Chemotherapy and Pharmacology, (2020), 85, 3, (621-626), 10.1007/s00280-020-04037-9)
Babiker, HM, Milhem, M, Aisner, J, Edenfield, W, Shepard, D, Savona, M, Iyer, S, Abdelrahim, M, Beach, CL, Skikne, B, Laille, E, Tsai, KT & Ho, T 2020, , Cancer Chemotherapy and Pharmacology, vol. 85, no. 5, pp. 1009-1010. https://doi.org/10.1007/s00280-020-04056-6

Renal Toxicity
Abdelrahim, M & Abudayyeh, A 2020, . in Advances in Experimental Medicine and Biology. vol. 1244, Advances in Experimental Medicine and Biology, vol. 1244, Springer, pp. 287-293. https://doi.org/10.1007/978-3-030-41008-7_16

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
Babiker, HM, Milhem, M, Aisner, J, Edenfield, W, Shepard, D, Savona, M, Iyer, S, Abdelrahim, M, Beach, CL, Skikne, B, Laille, E, Tsai, KT & Ho, T 2020, , Cancer Chemotherapy and Pharmacology, vol. 85, no. 3, pp. 621-626. https://doi.org/10.1007/s00280-020-04037-9